金水宝胶囊联合厄贝沙坦对糖尿病肾病患者的临床疗效
|
摘要
目的探讨金水宝胶囊联合厄贝沙坦对糖尿病肾病患者的临床疗效。方法 82例患者随机分为观察组和对照组,每组41例。对照组给予厄贝沙坦,观察组在对照组基础上加用金水宝胶囊,4周为1个疗程。然后,分析总有效率、空腹血糖、收缩压、舒张压、血管内皮功能指标、细胞因子、生活质量量表评分变化。结果观察组总有效率显著高于对照组(P<0. 05)。治疗后,2组空腹血糖、收缩压、舒张压、ET-1、TNF-α、IL-6显著降低(P<0. 05),NO、生活质量量表评分显著升高(P<0. 05),以观察组更显著(P<0. 05)。结论金水宝胶囊联合厄贝沙坦临床疗效良好,可有效改善糖尿病肾病患者血管内皮功能、细胞因子水平、生活质量。
AIM To explore the clinical effects of Jinshuibao Capsules combined with irbesartan on patients with diabetic nephropathy. METHODS Eighty-two patients were randomly divided into control group for an intervention of 4-week irbesartan and observation group for 4-week Jinshuibao Capsules on the basis of irbesartan,41 cases in each group. Subsequently,the changes in total effective rate,fasting blood glucose,systolic blood pressure,diastolic blood pressure,vascular endothelial function indices,cytokines and life quality scale scores were analyzed. RESULTS The observation group demonstrated significantly higher total effective rate than the control group( P< 0. 05). Both groups shared markedly decrease in post-treatment fasting blood glucose,systolic blood pressure,diastolic blood pressure,ET-1,TNF-α and IL-6( P<0. 05),obvious improvement of NO and life quality scale scores( P < 0. 05), among which the observation group demonstrated its superiorities( P < 0. 05).CONCLUSION The combination therapy of Jinshuibao Capsules and irbesartan shed light on the treatment of diabetic nephropathic patients as revealed by the good clinical outcome of improvement in vascular endothelial function,cytokine levels and life quality.
AIM To explore the clinical effects of Jinshuibao Capsules combined with irbesartan on patients with diabetic nephropathy. METHODS Eighty-two patients were randomly divided into control group for an intervention of 4-week irbesartan and observation group for 4-week Jinshuibao Capsules on the basis of irbesartan,41 cases in each group. Subsequently,the changes in total effective rate,fasting blood glucose,systolic blood pressure,diastolic blood pressure,vascular endothelial function indices,cytokines and life quality scale scores were analyzed. RESULTS The observation group demonstrated significantly higher total effective rate than the control group( P< 0. 05). Both groups shared markedly decrease in post-treatment fasting blood glucose,systolic blood pressure,diastolic blood pressure,ET-1,TNF-α and IL-6( P<0. 05),obvious improvement of NO and life quality scale scores( P < 0. 05), among which the observation group demonstrated its superiorities( P < 0. 05).CONCLUSION The combination therapy of Jinshuibao Capsules and irbesartan shed light on the treatment of diabetic nephropathic patients as revealed by the good clinical outcome of improvement in vascular endothelial function,cytokine levels and life quality.
引文
[1] Shahzad K,Bock F,Dong W,et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy[J]. Kidney Int,2015,87(1):74-84.
[2]余翠,熊钱颖,王李卓,等.糖尿病肾病的发病机制及治疗进展[J].医学综述,2015,21(21):3944-3947.
[3]张舒媛,王东超,李博,等.糖尿病肾病研究进展[J].世界中医药,2015,10(10):1621-1625.
[4] Barutta F,Bruno G,Grimaldi S,et al. Inflammation in diabetic nephropathy:moving toward clinical biomarkers and targets for treatment[J]. Endocrine,2015,48(3):730-742.
[5] Fiseha T. Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients[J]. Biomark Res,2015,3:16.
[6]柴剑丽,吴春燕,王文娟,等.糖尿病肾病患者血液透析中低血糖管理的持续质量改进[J].中华护理杂志,2015,50(2):170-174.
[7]陈灏珠,钟南山,陆再英.内科学[M]. 8版.北京:人民卫生出版社,2013:741.
[8] Huang W,Huang J,Liu Q,et al. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy[J]. Clin Endocrinol(Oxf), 2015, 82(2):229-233.
[9] Lv M,Chen Z,Hu G Y,et al. Therapeutic strategies of diabetic nephropathy:recent progress and future perspectives[J]. Drug Discov Today,2015,20(3):332-346.
[10]王先惠.厄贝沙坦联合黄芪注射液治疗老年糖尿病肾病患者疗效及对微循环障碍和氧化应激指标的影响[J].海南医学院学报,2015,21(12):1636-1639.
[11]张阳敏.银杏达莫注射液联合厄贝沙坦片治疗糖尿病肾病的临床研究[J].河北医药,2015,37(20):3107-3109.
[12]岳玉和,王丽,刘文军.平糖益肾汤联合厄贝沙坦治疗早期糖尿病肾病患者疗效研究[J].辽宁中医药大学学报,2016,18(5):195-197.
[13]刘阳,吴艳,喻荷淋,等.格列齐特结合舒洛地特对2型糖尿病早期肾病患者血管内皮功能的影响[J].广西医科大学学报,2016,33(2):325-327.
[14]付饶,刘渤,张桂红.前列地尔对早期糖尿病肾病患者血管内皮功能的影响[J].中国中西医结合肾病杂志,2015,16(5):446-447.
[15]刘文雪,孙逸君,孙铭,等.高尿酸血症对糖尿病肾病患者血管内皮功能的影响[J].中国医师杂志,2017,19(5):755-757.
[16]江思瑜,梁婵,吴晓光.利拉鲁肽对糖尿病肾病患者炎症因子影响的研究进展[J].中国药房,2017,28(2):280-283.
[17]袁峰.益气健脾补肾法对糖尿病肾病患者炎症因子及肾功能的影响[J].系统医学,2016,1(3):20-22.
[18]陈盛业,杨凯,董佳妮,等.益气养阴中药对糖尿病肾病患者炎症因子及血管内皮因子的影响[J].中医药信息,2016,33(1):46-49.
[2]余翠,熊钱颖,王李卓,等.糖尿病肾病的发病机制及治疗进展[J].医学综述,2015,21(21):3944-3947.
[3]张舒媛,王东超,李博,等.糖尿病肾病研究进展[J].世界中医药,2015,10(10):1621-1625.
[4] Barutta F,Bruno G,Grimaldi S,et al. Inflammation in diabetic nephropathy:moving toward clinical biomarkers and targets for treatment[J]. Endocrine,2015,48(3):730-742.
[5] Fiseha T. Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients[J]. Biomark Res,2015,3:16.
[6]柴剑丽,吴春燕,王文娟,等.糖尿病肾病患者血液透析中低血糖管理的持续质量改进[J].中华护理杂志,2015,50(2):170-174.
[7]陈灏珠,钟南山,陆再英.内科学[M]. 8版.北京:人民卫生出版社,2013:741.
[8] Huang W,Huang J,Liu Q,et al. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy[J]. Clin Endocrinol(Oxf), 2015, 82(2):229-233.
[9] Lv M,Chen Z,Hu G Y,et al. Therapeutic strategies of diabetic nephropathy:recent progress and future perspectives[J]. Drug Discov Today,2015,20(3):332-346.
[10]王先惠.厄贝沙坦联合黄芪注射液治疗老年糖尿病肾病患者疗效及对微循环障碍和氧化应激指标的影响[J].海南医学院学报,2015,21(12):1636-1639.
[11]张阳敏.银杏达莫注射液联合厄贝沙坦片治疗糖尿病肾病的临床研究[J].河北医药,2015,37(20):3107-3109.
[12]岳玉和,王丽,刘文军.平糖益肾汤联合厄贝沙坦治疗早期糖尿病肾病患者疗效研究[J].辽宁中医药大学学报,2016,18(5):195-197.
[13]刘阳,吴艳,喻荷淋,等.格列齐特结合舒洛地特对2型糖尿病早期肾病患者血管内皮功能的影响[J].广西医科大学学报,2016,33(2):325-327.
[14]付饶,刘渤,张桂红.前列地尔对早期糖尿病肾病患者血管内皮功能的影响[J].中国中西医结合肾病杂志,2015,16(5):446-447.
[15]刘文雪,孙逸君,孙铭,等.高尿酸血症对糖尿病肾病患者血管内皮功能的影响[J].中国医师杂志,2017,19(5):755-757.
[16]江思瑜,梁婵,吴晓光.利拉鲁肽对糖尿病肾病患者炎症因子影响的研究进展[J].中国药房,2017,28(2):280-283.
[17]袁峰.益气健脾补肾法对糖尿病肾病患者炎症因子及肾功能的影响[J].系统医学,2016,1(3):20-22.
[18]陈盛业,杨凯,董佳妮,等.益气养阴中药对糖尿病肾病患者炎症因子及血管内皮因子的影响[J].中医药信息,2016,33(1):46-49.